The GX-03 phase II trial in atopic dermatitis uses a staged adaptive design, showing strong efficacy and safety in interim results, especially among patients with higher pruritus scores. Stage 2 will enroll up to 135 patients, with a data readout expected in Q4 2026 and phase III targeted for mid-2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.